Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.37 |
| ▸ | UBE2M | P61081 | 12/20 | 0.33 |
| ▸ | DCUN1D1 | Q96GG9 | 12/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26949134 | 0.82 | HRH3 (0.43) | HRH3SMN1; SMN2 | |
| SCHEMBL19629041 | 0.78 | KDM4E (0.40) | SMN1; SMN2 | |
| SCHEMBL29307074 | 0.76 | HRH3 (0.39) | HRH3 | |
| SCHEMBL29348172 | 0.75 | NPC1 (0.36) | HRH3OPRM1OPRL1SMN1; SMN2 | |
| SCHEMBL23134534 | 0.75 | HRH3 (0.48) | HRH3SMN1; SMN2 | |
| SCHEMBL23133948 | 0.74 | HRH3 (0.47) | HRH3SMN1; SMN2 | |
| SCHEMBL25447572 | 0.72 | SIGMAR1 (0.46) | UBE2MDCUN1D1OPRM1OPRL1 | |
| SCHEMBL27269252 | 0.72 | HRH3 (0.41) | HRH3OPRM1SMN1; SMN2 | |
| SCHEMBL25090277 | 0.72 | OPRM1 (0.36) | UBE2MDCUN1D1OPRM1OPRL1 | |
| SCHEMBL24608216 | 0.72 | HSD11B1 (0.43) | HRH3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398117-A1 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| US-11541056-B2 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide derivatives | NOVARTIS AG (CH) | 2023-01-03 | — | — | US | disclosed |
| US-20210251996-A1 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives | NOVARTIS AG (CH) | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11541056-B2 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide derivatives | PAH, PKD1, REN | HRH3 531/4885UBE2M 4404/4885DCUN1D1 3488/4885 |
| US-20230398117-A1 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives | PAH, PKD1, REN | HRH3 531/4885UBE2M 4404/4885DCUN1D1 3488/4885 |
| US-20210251996-A1 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives | PAH, PKD1, REN | HRH3 531/4885UBE2M 4404/4885DCUN1D1 3488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.